CAR-T therapy

Oncology

Expanding the haematology toolkit: Insights and operational ...

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

News

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

Oncology

ASCO 2025 interview with Dr Jason Westin

Breaking barriers to CAR T-cell therapy: The vision for expa...

Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.

R&D

Purity, potency, and safety – affordably – in stem cell ther...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s

News

JPM: Precision Bio continues offload of CAR-T rights

Precision BioSciences has agreed to a second licensing deal for its ‘off-the-shelf’ CAR-T therapy azer-cel, as it switches focus to developing in vivo applications of its

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

Expanding the haematology toolkit: Insights and operational ...

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

Breaking barriers to CAR T-cell therapy: The vision for expa...

Purity, potency, and safety – affordably – in stem cell ther...

JPM: Precision Bio continues offload of CAR-T rights

Leschly steps down as 2seventy wields the axe

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

CAR-T therapy

Editor's Picks